



Pfizer Inc
235 East 42nd Street
New York, NY 10017

Notice to 340B Covered Entities Regarding Panzyga Immune Globulin Intravenous (Human) 10% Liquid Preparation

This notice provides information for 340B covered entities about how to acquire Panzyga Immune Globulin Intravenous (Human) 10% Liquid Preparation (Panzyga) at the 340B ceiling price. Panzyga is indicated for primary humoral immunodeficiency in patients two years of age and older, and chronic immune thrombocytopenic purpura in adults. Pfizer, Inc. (Pfizer) markets Panzyga under the following NDCs:¹

Description	Carton NDC
PANZYGA IVIG 1000mg/10mL SSOL 1x1 VL	68982-0820-01
PANZYGA IVIG 2500mg/25mL SSOL 1x1 VL	68982-0820-02
PANZYGA IVIG 5000mg/50mL SSOL 1x1 VL	68982-0820-03
PANZYGA IVIG 10000mg/100mL SSOL 1x1 VL	68982-0820-04
PANZYGA IVIG 20000mg/200mL SSOL 1x1 VL	68982-0820-05
PANZYGA IVIG 30000mg/500mL SSOL 1x1 VL	68982-0820-06

Currently, the supply of Panzyga is insufficient to meet the demand. Accordingly, Pfizer relies on a defined distribution network to distribute Panzyga. The network consists of specialty distributors, who will sell through to select home infusion providers and specialty pharmacies. In addition, due to the limited supply of Panzyga, Pfizer has implemented an allocation procedure. Under the procedure, Pfizer has designated a specified proportion of Panzyga (based on previous purchase volume of customers in classes of trade the same or similar to 340B classes of trade) for purchase by 340B covered entities. Covered entities wishing to purchase Panzyga may contact ASD Healthcare using the information below:

ASD Healthcare
3101 Gaylord Parkway
Frisco, TX 75035
800-746-6273
www.asdhealthcare.com

¹ Under an arrangement among Octapharma AG and Octapharma USA, Inc. (together, Octapharma) and Pfizer, Octapharma has granted Pfizer an exclusive license to commercialize Panzyga in the United States. Pfizer currently is in the process of obtaining NDCs for Panzyga, and in the interim, Panzyga is being distributed under the Octapharma labeler code.



Alternatively, if a 340B covered entity prefers to order from another specialty distributor, it can do so, and ASD will drop ship Panzyga to the distributor of the covered entity's choice.

Pfizer takes its obligations under the 340B program seriously and developed its network in an evenhanded manner that treats all purchases equally, and does not discriminate against 340B covered entities. As such, this defined distribution network and allocation procedure complies fully with the relevant 340B program guidance. If you have any questions regarding the distribution of Panzyga, or experience any difficulty obtaining any of these products at the 340B ceiling price for your eligible patients, please contact Paul Hiley at 212-733-8893.